Effects of Gastric Cancer Cells on the Differentiation of Treg Cells

  • Hu, Jing-Lan (Department of Digestive Internal Medicine, Zhumadian Central Hospital) ;
  • Yang, Zhen (Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University) ;
  • Tang, Jian-Rong (Department of Digestive Internal Medicine, Zhumadian Central Hospital) ;
  • Fu, Xue-Qin (Department of Digestive Internal Medicine, Zhumadian Central Hospital) ;
  • Yao, Lan-Jie (Department of Digestive Internal Medicine, Zhumadian Central Hospital)
  • 발행 : 2013.08.30


The aim of this study was evaluated the prevalence of Treg cells in peripheral blood in patients with gastric cancer, and investigate the effect of gastric cancer cells on their differentiation. ELISA was employed to assess the concentrations of TGF-${\beta}$ and IL-10 in gastric cancer patients' serum. Then, mouse gastric cancer cells were co-cultured with T lymphocytes or T lymphocytes + anti-TGF-${\beta}$. Flow cytometric analysis and RT-PCR were then performed to detect Treg cells and TGF-${\beta}$ and IL-10 expression in gastric cancer cells. Our data showed that the expression of TGF-${\beta}$ and IL-10 in the patients with gastric cancer was increased compared to the case with healthy donors. The population of Treg cells and the expression levels of TGF-${\beta}$ and IL-10 in the co-culture group were much higher than in the control group (18.6% vs 9.5%) (P<0.05). Moreover, the population of Treg cells and the expression levels of TGF-${\beta}$ and IL-10 in the co-culture systerm were clearly decreased after addition of anti-TGF-${\beta}$ (7.7% vs 19.6%) (P<0.01). In conclusion, gastric cancer cells may induce Treg cell differentiation through TGF-${\beta}$, and further promote immunosuppression.


  1. Achyut BR, Yang L (2011). Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology, 141, 1167-78.
  2. Decker T, Fischer G, Bucke W, et al (2012). Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer. J Cancer Res Clin Oncol, 138, 1945-50.
  3. Erfani N, Mehrabadi SM, Ghayumi MA, et al (2012). Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer, 77, 306-11.
  4. Huber S, Schramm C (2006). TGF-beta and CD4+CD25+ regulatory T cells. Front Biosci, 11, 1014-23.
  5. Kue CS, Lim HX, Jung MY, et al (2013). C6-ceramide in combination with transforming growth factor-$\beta$ enhances Treg cell differentiation and stable FoxP3 expression in vitro and in vivo. Immunobiology, 218, 952-9.
  6. Li MO, Wan YY, Sanjabi S, et al (2006). Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol, 24, 99-146.
  7. Lindau D, Gielen P, Kroesen M, et al (2013). The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology, 138, 105-15.
  8. Mishra L, Katuri V, Evans S (2005). The role of PRAJA and ELF in TGF-beta signaling and gastric cancer. Cancer Biol Ther, 4, 694-9.
  9. Nakamura T, Shima T, Saeki A, et al (2007). Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci, 98, 874-81.
  10. Narita Y, Kitamura H, Wakita D, et al (2013). The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice. J Immunol, 190, 812-20.
  11. Regateiro FS, Howie D, Cobbold SP, et al (2011). TGF-beta in transplantation tolerance. Curr Opin Immunol, 23, 660-9.
  12. Sakuishi K, Ngiow SF, Sullivan JM, et al (2013). TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology, 2, e23849.
  13. Santin AD, Bellone S, Ravaggi A, et al (2001). Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG, 108, 804-8.
  14. Shen WD, Liu PF, Liu BT, et al (2012). Expression and significance of TGF-β1 and Smad2 in gastric cancer. World Chin J Digest, 20, 1238-41.
  15. Stelmaszczyk-Emmel A, Zawadzka-Krajewska A, Szypowska A, et al (2013). Frequency and Activation of CD4+CD25 FoxP3+ Regulatory T Cells in Peripheral Blood from Children with Atopic Allergy. Int Arch Allergy Immunol, 162, 16-24.
  16. Thun MJ, DeLancey JO, Center MM, et al (2010). The global burden of cancer: priorities for prevention. Carcinogenesis, 31, 100-10.
  17. Weiss VL, Lee TH, Song H, et al (2012). Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS One, 7, e31962.
  18. Wicherek L, Jozwicki W, Windorbska W, et al (2011). Analysis of Treg cell population alterations in the peripheral blood of patients treated surgically for ovarian cancer - a preliminary report. Am J Reprod Immunol, 66, 444-50.
  19. Zou W (2006). Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol, 6, 295-307.

피인용 문헌

  1. Tumor-Derived Transforming Growth Factor-β is Critical for Tumor Progression and Evasion from Immune Surveillance vol.15, pp.13, 2014,
  2. Tumor-derived CD4+CD25+ Tregs Inhibit the Maturation and Antigen-Presenting Function of Dendritic Cells vol.16, pp.7, 2015,